Navigation Links
Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
Date:11/7/2007

SAN DIEGO, CA, Nov. 7 /PRNewswire-FirstCall/ - Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today financial results for the third quarter ended September 30, 2007. All amounts, unless specified otherwise, are in Canadian dollars.

Nventa reported a net loss of $3.1 million or $0.01 per share, for the three months ended September 30, 2007, compared to a net loss of $2.3 million, or $0.03 per share, for the same period in 2006. For the nine months ended September 30, 2007, the Company reported a net loss of $10.1 million, or $0.05 per share, compared to a net loss of $8.0 million, or $0.10 per share, for the same period in 2006. The Company's net loss for the nine months ended September 30, 2007 included approximately $0.8 million in one-time corporate restructuring expenses.

The Company had cash and cash equivalents of $14.3 million as of September 30, 2007.

RECENT NVENTA HIGHLIGHTS

- Initiated and dosed the first cohort of patients in the Company's

HspE7 Phase 1 clinical trial in cervical intraepithelial neoplasia;

- Raised $8.6 million in additional capital through a Short Form

Prospectus Offering;

- Strengthened management team with addition of David Duncan Jr.,

Vice President of Finance;

- Assembled distinguished group of international experts for Clinical

and Scientific Advisory Board;

- Presented additional data at the 24th International Papillomavirus

Conference and Clinical Workshop that demonstrate that new HspE7

promotes more potent immune responses;

- Granted new U.S. patent for Nventa's CoVal(TM) fusions covering their

use in patients with human papillomavirus (HPV)-related diseases;

- Published data in Clinical and Vaccine Immunology demonstrating

ability of new HspE7 to elicit long-lasting tumor protection in vivo,

suggesting that HspE7 may have utility in (HPV)-infected patients

with invasive cancer and/or HIV;

- Published new immunological data in Gynecologic Oncology from a

Phase 2 clinical trial testing previous version of HspE7; 95 percent

of cervical dysplasia patients had regression or stable disease in

the study.

"We achieved many important milestones during this quarter," said Gregory M. McKee, President and Chief Executive Officer at Nventa. "With additional finances, depth and experience of the Board and Management team, and an impressive Clinical and Scientific Advisory Board, we are advancing HspE7, our lead therapeutic vaccine candidate, through clinical trials and are exploring ways to expand and progress our preclinical pipeline as well."

About Nventa Biopharmaceuticals Corporation:

--------------------------------------------

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.

The Audit Committee of the Company has reviewed and approved of the contents of this Press Release. Summary financials are attached below. The full financial statements and MD&A for the three and nine months ended September 30, 2007 can be found on SEDAR at http://www.sedar.com.

(financial information attached)

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

(Unaudited)

(Canadian dollars) (In thousands, except per share amounts)

Three months ended Nine months ended

September 30, September 30,

-------------------- --------------------

2007 2006 2007 2006

--------- --------- --------- ---------

Revenue:

Collaborative R&D revenue $ 155 $ 155 $ 465 $ 465

Operating expenses:

Research and development 1,509 1,484 5,047 5,764

Selling, general and

administrative 1,177 1,004 3,607 2,851

Corporate restructuring 20 - 814 -

--------- --------- --------- ---------

2,706 2,488 9,468 8,615

--------- --------- --------- ---------

Operating loss (2,551) (2,333) (9,003) (8,150)

Other income (expense):

Interest and other income,

net 159 72 430 121

Foreign exchange (loss)

gain, net (693) (15) (1,521) 5

--------- --------- --------- ---------

(534) 57 (1,091) 126

--------- --------- --------- ---------

Net loss $ (3,085) $ (2,276) $(10,094) $ (8,024)

--------- --------- --------- ---------

--------- --------- --------- ---------

--------- --------- --------- ---------

Basic and diluted loss

per common share: $ (0.01) $ (0.03) $ (0.05) $ (0.10)

--------- --------- --------- ---------

--------- --------- --------- ---------

Weighted average common

shares outstanding

(in thousands) 221,139 83,456 196,138 83,285

--------- --------- --------- ---------

--------- --------- --------- ---------

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(Unaudited)

(Canadian dollars in thousands)

September 30, December 31,

2007 2006

------------- -------------

Cash and cash equivalents $ 14,345 $ 2,972

Total assets 16,348 4,619

Stockholders' equity 14,956 2,303

Total shares outstanding (in thousands) 260,586 83,669

CONTACT: Gregory McKee, President and Chief Executive Officer, 9381 Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4940, gmckee@nventacorp.com; Donna Slade, Director, Investor Relations, 9381 Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945, dslade@nventacorp.com


'/>"/>
SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
2. Nventa announces publication of HspE7 data
3. Nventas CEO to present at two upcoming investor conferences
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
9. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
10. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
11. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... The American Medical Informatics ... of the National Coordinator for Health IT (ONC) outlining a measurement approach to ... were available when and where it was needed. The organization of health informatics ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute (WPI) ... of wound healing and tissue regeneration. , The novel method, developed by WPI ...
(Date:5/23/2016)... ... May 23, 2016 , ... PrecisionAg® Media has released ... and Beyond. The paper outlines the key trends that are creating both opportunities ... witnessed a lot of highs and lows as the precision agriculture market has ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman Prizes. ... are given in two categories, one for experiment and the other for theory ...
Breaking Biology Technology:
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/15/2016)... March 15, 2016 Yissum Research Development ... technology-transfer company of the Hebrew University, announced today the ... sensing technology of various human biological indicators. Neteera Technologies ... million from private investors. ... the detection of electromagnetic emissions from sweat ducts, enables ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
Breaking Biology News(10 mins):